<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: commercialization", fill: "#a1caf1"},
{source: "6: commercialization", target: "6: lead products", fill: "#a1caf1"},
{source: "6: lead products", target: "6: ProQuin XR and Glumetza", fill: "#a1caf1"},
{source: "6: commercialization", target: "7: two lead products", fill: "#ff7f00"},
{source: "7: two lead products", target: "7: ProQuin XR ", fill: "#ff7f00"},
{source: "7: ProQuin XR ", target: "7: approved by", fill: "#ff7f00"},
{source: "7: approved by", target: "7: candidates", fill: "#ff7f00"},
{source: "7: candidates", target: "7: development", fill: "#ff7f00"},
{source: "7: two lead products", target: "17: generate sales", fill: "#78866b"},
{source: "17: generate sales", target: "17: candidates", fill: "#78866b"},
{source: "17: candidates", target: "17: regulatory approval", fill: "#78866b"},
{source: "17: regulatory approval", target: "17: must substantially enhance", fill: "#78866b"},
{source: "17: must substantially enhance", target: "17: internal marketing", fill: "#78866b"},
{source: "17: internal marketing", target: "17: distribution", fill: "#78866b"},
{source: "17: distribution", target: "17: capabilities", fill: "#78866b"},
{source: "17: capabilities", target: "17: arrangements with third parties", fill: "#78866b"},
{source: "17: generate sales", target: "29: product candidates", fill: "#29ab87"},
{source: "29: product candidates", target: "29: at early stages", fill: "#29ab87"},
{source: "29: at early stages", target: "29: development", fill: "#29ab87"},
{source: "29: development", target: "29: market acceptance", fill: "#29ab87"},
{source: "29: product candidates", target: "31: assisting us with", fill: "#dda0dd"},
{source: "31: assisting us with", target: "31: preparation", fill: "#dda0dd"},
{source: "31: preparation", target: "31: feasibility", fill: "#dda0dd"},
{source: "31: feasibility", target: "31: combination", fill: "#dda0dd"},
{source: "31: combination", target: "31: the AcuForm ", fill: "#dda0dd"},
{source: "31: the AcuForm ", target: "31: technology", fill: "#dda0dd"},
{source: "31: technology", target: "31: collaborative", fill: "#dda0dd"},
{source: "31: assisting us with", target: "39: following factors will affect", fill: "#c54b8c"},
{source: "39: following factors will affect", target: "39: Glumetza in the United States ", fill: "#c54b8c"},
{source: "39: Glumetza in the United States ", target: "39: of ProQuin XR and Glumetza ", fill: "#c54b8c"},
{source: "39: of ProQuin XR and Glumetza ", target: "39: variations", fill: "#c54b8c"},
{source: "39: variations", target: "39: from collaborative agreements", fill: "#c54b8c"},
{source: "39: from collaborative agreements", target: "39: milestone payments royalties license fees", fill: "#c54b8c"},
{source: "39: milestone payments royalties license fees", target: "39: contract revenues", fill: "#c54b8c"},
{source: "39: contract revenues", target: "39: decisions by collaborative partners", fill: "#c54b8c"},
{source: "39: decisions by collaborative partners", target: "39: proceed with", fill: "#c54b8c"},
{source: "39: proceed with", target: "39: subsequent phases", fill: "#c54b8c"},
{source: "39: subsequent phases", target: "39: collaboration", fill: "#c54b8c"},
{source: "39: collaboration", target: "39: market acceptance", fill: "#c54b8c"},
{source: "39: market acceptance", target: "39: technology", fill: "#c54b8c"},
{source: "39: technology", target: "39: regulatory actions", fill: "#c54b8c"},
{source: "39: regulatory actions", target: "39: new technologies", fill: "#c54b8c"},
{source: "39: new technologies", target: "39: developments", fill: "#c54b8c"},
{source: "39: developments", target: "39: concerning", fill: "#c54b8c"},
{source: "39: concerning", target: "39: proprietary", fill: "#c54b8c"},
{source: "39: proprietary", target: "39: infringement allegations", fill: "#c54b8c"},
{source: "39: infringement allegations", target: "39: litigation matters", fill: "#c54b8c"},
{source: "39: litigation matters", target: "39: introduction", fill: "#c54b8c"},
{source: "39: introduction", target: "39: new products by", fill: "#c54b8c"},
{source: "39: new products by", target: "39: competitors", fill: "#c54b8c"},
{source: "39: competitors", target: "39: manufacturing costs", fill: "#c54b8c"},
{source: "39: manufacturing costs", target: "39: difficulties", fill: "#c54b8c"},
{source: "39: difficulties", target: "39: clinical trials", fill: "#c54b8c"},
{source: "39: clinical trials", target: "39: government funding", fill: "#c54b8c"},
{source: "39: government funding", target: "39: thirdparty reimbursement policies", fill: "#c54b8c"},
{source: "39: thirdparty reimbursement policies", target: "39: compliance with", fill: "#c54b8c"},
{source: "39: following factors will affect", target: "START_HERE", fill: "#c54b8c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assertio_Therapeutics">Assertio Therapeutics</a></td>
      <td>Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ciprofloxacin">Ciprofloxacin</a></td>
      <td>Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Nintendo_Switch_games_(0–9_and_A)">List of Nintendo Switch games (0–9 and A)</a></td>
      <td>This is the first part of the list of Nintendo Switch games.\n\n\n== List ==\nThere are currently 4375 games across this page (0–A), List of Nintendo Switch games (B), List of Nintendo Switch games (C–G), List of Nintendo Switch games (H–P), and List of Nintendo Switch games (Q–Z).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DEPOMED INC      Item 1A            Risk Factors               In addition to other information in this report, the <font color="blue">following factors</font>     should be considered <font color="blue">carefully</font> in evaluating our company</td>
    </tr>
    <tr>
      <td>We believe the     following risks, along with the <font color="blue">risks described</font> elsewhere in this Form 10-K,     including the <font color="blue">risks described</font> above under “BUSINESS – Competition, – Patents     and Proprietary Rights, – Manufacturing, – Marketing and Sales, – Government     Regulation, – Product Liability, and –Employees”, are the material risks we     face at the present time</td>
    </tr>
    <tr>
      <td>If any of the risks or <font color="blue"><font color="blue">uncertainties</font> described</font> in     this Form 10-K actually occurs, our business, results of <font color="blue">operations</font> or     <font color="blue">financial condition could</font> be <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>The risks and     <font color="blue"><font color="blue">uncertainties</font> described</font> in this Form 10-K are not the <font color="blue">only ones facing</font> the     company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> of which we are unaware or     currently deem <font color="blue">immaterial may also become important factors</font> that may harm     our business</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________         We  depend  heavily  on  our  marketing  partners  for  the successful     <font color="blue">commercialization</font> of our <font color="blue">lead products</font>, <font color="blue"><font color="blue">ProQuin XR </font>and Glumetza</font></td>
    </tr>
    <tr>
      <td>Our two <font color="blue">lead products</font>, <font color="blue">ProQuin XR </font>and the 500mg strength Glumetza, have been     <font color="blue">approved by</font> the FDA Our other product <font color="blue">candidates</font> are in earlier stages of     clinical or preclinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We anticipate that in the near term our     <font color="blue">success will depend on royalties generated from sales</font> of <font color="blue">ProQuin XR </font>and     sales of Glumetza</td>
    </tr>
    <tr>
      <td>We have <font color="blue">licensed exclusive marketing rights</font> to <font color="blue">ProQuin XR </font>in the United     States to Esprit Pharma, Inc</td>
    </tr>
    <tr>
      <td>Esprit launched <font color="blue">ProQuin XR </font>in November 2005</td>
    </tr>
    <tr>
      <td>If Esprit fails to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> ProQuin XR, our business,     financial  condition  and results of <font color="blue">operations</font> will be <font color="blue">materially</font> and     <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">licensed exclusive marketing rights</font> to the 500mg Glumetza in Canada     to Biovail</td>
    </tr>
    <tr>
      <td>Biovail launched the 500mg <font color="blue">Glumetza in Canada in November </font>2005</td>
    </tr>
    <tr>
      <td><font color="blue">If Biovail </font>fails to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> Glumetza, our business and     <font color="blue">future revenues will</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>If we fail to enhance our marketing, sales and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>, or     fail to <font color="blue"><font color="blue">enter into</font> <font color="blue"><font color="blue">arrangements</font> with third parties</font></font>, we will not be able to     create a market for <font color="blue">Glumetza in the United States</font></td>
    </tr>
    <tr>
      <td>Currently, we have limited sales and <font color="blue">marketing staff</font>, and <font color="blue">no <font color="blue">distribution</font></font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">generate sales</font> of Glumetza or any other product     <font color="blue">candidates</font> that receive <font color="blue"><font color="blue">regulatory</font> approval</font> that we choose to market or     co-market, we <font color="blue">must substantially enhance</font> our <font color="blue">internal marketing</font> and sales     force  with  technical  expertise  and  with  supporting  <font color="blue">distribution</font>     <font color="blue">capabilities</font>, or make <font color="blue"><font color="blue">arrangements</font> with third parties</font> to perform these     services for us</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of a sales and <font color="blue">distribution</font> infrastructure     requires  substantial resources, which may divert the attention of our     <font color="blue">management</font> and <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>To the extent that we <font color="blue">enter into</font> marketing and     sales <font color="blue">arrangements</font> with other companies, our revenues will depend on the     efforts of others</td>
    </tr>
    <tr>
      <td>These <font color="blue">efforts may</font> not be successful</td>
    </tr>
    <tr>
      <td>If we fail to fully     develop  sales,  marketing  and  <font color="blue">distribution</font>  channels, or <font color="blue">enter into</font>     <font color="blue"><font color="blue">arrangements</font> with third parties</font>, we will experience delays in <font color="blue">product sales</font>     and <font color="blue">incur increased costs</font></td>
    </tr>
    <tr>
      <td>To date, we have had limited revenues from license fees, <font color="blue">product sales</font>,     <font color="blue"><font color="blue">collaborative</font> research</font> and <font color="blue">development</font> <font color="blue">arrangements</font> and <font color="blue"><font color="blue">feasibility</font> studies</font>,     although we have received dlra55 million in <font color="blue">license fees from</font> Biovail and     Esprit in 2005</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, we had <font color="blue">total revenues</font>     of dlra4dtta4 million and for the years ended <font color="blue">December </font>31, 2004 and 2003, we had     <font color="blue">total revenues</font> of dlra200cmam000 and dlra1dtta0 million, respectively</td>
    </tr>
    <tr>
      <td>For the year     ended <font color="blue">December </font>31, 2005, we <font color="blue">incurred net losses</font> of dlra24dtta5 million and for the     years ended <font color="blue">December </font>31, 2004 and 2003, we <font color="blue">incurred net losses</font> of dlra26dtta9     million and dlra30dtta0 million, respectively</td>
    </tr>
    <tr>
      <td>As we continue our research and     <font color="blue">development</font> efforts, preclinical testing and <font color="blue"><font color="blue">clinical trial</font> activities</font>, and     expand our sales and <font color="blue">marketing organization</font>, we anticipate that we will     continue to incur substantial operating losses for at least the next year</td>
    </tr>
    <tr>
      <td>Therefore, we expect our <font color="blue">cumulative losses</font> to increase</td>
    </tr>
    <tr>
      <td>These losses, among     other things, have had, and we expect that they <font color="blue">will continue</font> to have, an     adverse  impact  on our total assets, <font color="blue">shareholders</font>’ equity and working     capital</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> are <font color="blue">at early stages</font> of <font color="blue">development</font> and may not be     successful or achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>We are preparing for a <font color="blue">Phase III </font><font color="blue">clinical trial</font> of Gabapentin GR, and we     have  another  product  candidate in earlier stages of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In     addition, Biovail is <font color="blue">assisting us with</font> the <font color="blue">preparation</font> of a supplemental NDA     filing for the new 1000mg <font color="blue">formulation</font> of Glumetza, and we expect to begin     performing <font color="blue"><font color="blue">feasibility</font> studies</font> by the second quarter of 2006 with another     compound in <font color="blue">combination</font> with <font color="blue">the AcuForm </font><font color="blue">technology</font> for a <font color="blue">collaborative</font>     partner</td>
    </tr>
    <tr>
      <td>Our own product <font color="blue">candidates</font> and those of our <font color="blue">collaborative</font> partners     are subject to the risk that any or all of them are found to be <font color="blue">in<font color="blue">effective</font></font>     or unsafe, or <font color="blue">otherwise may fail</font> to receive <font color="blue"><font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> clearance</font>s</font></font></td>
    </tr>
    <tr>
      <td>We are unable to <font color="blue">predict whether</font> any of these other product <font color="blue">candidates</font> will     receive <font color="blue"><font color="blue"><font color="blue">regulatory</font> clearance</font>s</font> or be <font color="blue"><font color="blue">successfully</font> <font color="blue">manufacture</font>d</font> or marketed</td>
    </tr>
    <tr>
      <td>Further, due to the <font color="blue">extended testing</font> and <font color="blue"><font color="blue">regulatory</font> review process</font> required     before  marketing  clearance  can  be  obtained,  the  time frames for     <font color="blue">commercialization</font> of any products are long and uncertain</td>
    </tr>
    <tr>
      <td>Even if these     other product <font color="blue">candidates</font> receive <font color="blue"><font color="blue">regulatory</font> clearance</font>, our <font color="blue">products may</font> not     achieve or maintain <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>Also, all of our product <font color="blue">candidates</font>,     other than the 1000mg <font color="blue">formulation</font> of Glumetza, use <font color="blue">the AcuForm </font><font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If it is discovered that <font color="blue">the AcuForm </font><font color="blue">technology</font> could have adverse                                           14     ______________________________________________________________________         effects  or  other  <font color="blue">characteristics</font> that indicate it is unlikely to be     <font color="blue">effective</font>  as a <font color="blue">delivery system</font> for drugs or <font color="blue">therapeutics</font>, our product     <font color="blue">development</font> efforts and our business would be <font color="blue"><font color="blue">significant</font>ly harmed</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results <font color="blue">may fluctuate</font> and affect our stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font> will affect our quarterly operating results and may     result in a material adverse effect on our stock price:         •  the timing of the <font color="blue">commercial launch</font> of <font color="blue">Glumetza in the United States</font>;         •  the degree of <font color="blue">commercial success</font> of <font color="blue"><font color="blue">ProQuin XR </font>and Glumetza</font>;         •  <font color="blue">variations</font> in revenues obtained from <font color="blue">collaborative</font> <font color="blue">agreements</font>, including     milestone payments, royalties, license fees and other <font color="blue">contract revenues</font>;         •  decisions by <font color="blue">collaborative</font> partners to proceed or not to <font color="blue">proceed with</font>     <font color="blue">subsequent phases</font> of a <font color="blue">collaboration</font> or program;         •  <font color="blue">market acceptance</font> of <font color="blue">the AcuForm </font><font color="blue">technology</font>;         •  <font color="blue"><font color="blue">regulatory</font> actions</font>;         •  adoption of <font color="blue">new <font color="blue">technologies</font></font>;         •   <font color="blue">development</font>s  <font color="blue">concerning</font>  <font color="blue">proprietary</font>  rights,  including patents,     <font color="blue"><font color="blue">infringement</font> allegations</font> and <font color="blue"><font color="blue">litigation</font> matters</font>;         •  the <font color="blue">introduction</font> of <font color="blue">new products by</font> our <font color="blue">competitors</font>;         •  <font color="blue"><font color="blue">manufacturing</font> costs</font> and <font color="blue"><font color="blue">difficult</font>ies</font>;         •  results of <font color="blue">clinical trial</font>s for our products;         •  changes in <font color="blue"><font color="blue">government</font> funding</font>;         •  third-party <font color="blue">reimbursement</font> policies; and         •  the status of our <font color="blue">compliance with</font> the provisions of the Sarbanes-Oxley     Act of 2002</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborative</font> <font color="blue">arrangements</font> <font color="blue">may give rise</font> to <font color="blue">disputes over commercial</font>     terms, contract interpretation and ownership of our <font color="blue">intellectual property</font>     and <font color="blue">may <font color="blue">adversely affect</font></font> the <font color="blue">commercial success</font> of our products</td>
    </tr>
    <tr>
      <td>We currently have a <font color="blue">collaboration</font> agreement for <font color="blue">development</font> of product     <font color="blue">candidates</font> through the <font color="blue">feasibility</font> phase with <font color="blue">New River Pharmaceuticals</font></td>
    </tr>
    <tr>
      <td>In     addition,  we  have in the past and may in the future <font color="blue">enter into</font> other     <font color="blue">collaborative</font> <font color="blue">arrangements</font>, some of which have <font color="blue">been based on less <font color="blue">definitive</font></font>     <font color="blue">agreements</font>,  such  as  memoranda  of  understanding, material transfer     <font color="blue">agreements</font>, options or <font color="blue">feasibility</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>We may not execute <font color="blue">definitive</font>     <font color="blue">agreements</font> formalizing these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Collaborative </font><font color="blue">relationships</font> are     <font color="blue">generally complex</font> and <font color="blue">may give rise</font> to disputes regarding the relative     rights, obligations and revenues of the parties, including the ownership of     <font color="blue">intellectual property</font> and <font color="blue">associated rights</font> and obligations, especially when     the applicable <font color="blue">collaborative</font> provisions have not <font color="blue">been fully negotiated</font> and     documented</td>
    </tr>
    <tr>
      <td>Such disputes can delay <font color="blue"><font color="blue">collaborative</font> research</font>, <font color="blue">development</font> or     <font color="blue">commercialization</font> of <font color="blue">potential products</font>, and can lead to lengthy, expensive     <font color="blue">litigation</font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>The terms of <font color="blue">collaborative</font> <font color="blue">arrangements</font> may also     limit or <font color="blue">preclude us from</font> developing products or <font color="blue">technologies</font> developed     pursuant to such <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">collaborators</font> under these     <font color="blue">arrangements</font> might breach the terms of their respective <font color="blue">agreements</font> or fail     to prevent <font color="blue">infringement</font> of the <font color="blue">licensed patents by third parties</font></td>
    </tr>
    <tr>
      <td>Moreover,     negotiating <font color="blue">collaborative</font> <font color="blue">arrangements</font> often takes <font color="blue">considerably longer</font> to     conclude than the <font color="blue">parties initially</font> anticipate, <font color="blue">which could</font> cause us to     agree to less favorable <font color="blue">agreement terms</font> that delay or <font color="blue">defer recovery</font> of our     <font color="blue">development</font> costs and reduce the <font color="blue">funding available</font> to <font color="blue">support key programs</font></td>
    </tr>
    <tr>
      <td>We  may not be able to <font color="blue">enter into</font> future <font color="blue">collaborative</font> <font color="blue">arrangements</font> on     acceptable terms, which would harm our ability to develop and <font color="blue">commercialize</font>     our current and <font color="blue">potential future products</font></td>
    </tr>
    <tr>
      <td>Further, even if we do enter     into <font color="blue">collaboration</font> <font color="blue">arrangements</font>, it is possible that our <font color="blue">collaborative</font>     <font color="blue">partners may</font> not choose to develop and <font color="blue">commercialize</font> <font color="blue">products using</font> the     <font color="blue">AcuForm  </font><font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Other factors relating to <font color="blue">collaboration</font>s that may     <font color="blue">adversely affect</font> the <font color="blue">commercial success</font> of our products include:         •   any parallel <font color="blue">development</font> by a <font color="blue">collaborative</font> partner of <font color="blue">competitive</font>     <font color="blue">technologies</font> or products;                                           15     ______________________________________________________________________         •  <font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners that limit or <font color="blue">preclude us from</font>     developing products or <font color="blue">technologies</font>;         •  <font color="blue">premature termination</font> of a <font color="blue">collaboration</font> agreement; or         •       <font color="blue">failure by</font> a <font color="blue">collaborative</font> partner to <font color="blue">devote sufficient resources</font> to     the  <font color="blue">development</font>  and  commercial  sales of <font color="blue">products using</font> <font color="blue">the AcuForm </font>    <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Generally, our <font color="blue">collaborative</font> <font color="blue">arrangements</font> do not restrict our <font color="blue">collaborative</font>     <font color="blue">partners from competing with us</font> or restrict their ability to market or sell     <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>Our current and any future <font color="blue">collaborative</font> <font color="blue">partners may</font>     pursue  existing  or  other  <font color="blue">development</font>-stage products or <font color="blue">alternative</font>     <font color="blue">technologies</font> in preference to those being developed in <font color="blue">collaboration</font> with     us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborative</font> <font color="blue">partners may</font> also terminate their <font color="blue">collaborative</font>     <font color="blue">relationships</font> with us or <font color="blue">otherwise decide</font> not to <font color="blue">proceed with</font> <font color="blue">development</font>     and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font> to develop a <font color="blue">successful product</font></td>
    </tr>
    <tr>
      <td>If we do not develop a     <font color="blue">successful product</font> we may not be able to <font color="blue">raise additional funds</font></td>
    </tr>
    <tr>
      <td>The  drug <font color="blue">development</font> process is costly, time-consuming and subject to     <font color="blue">unpredictable delays</font> and failures</td>
    </tr>
    <tr>
      <td>Before we or others make <font color="blue">commercial sales</font>     of <font color="blue">products using</font> <font color="blue">the AcuForm </font><font color="blue">technology</font>, other than Glumetza and ProQuin     XR, we, our current and any future <font color="blue">collaborative</font> partners will need to:         •  <font color="blue">conduct preclinical</font> and <font color="blue">clinical tests showing</font> that these products are     safe and <font color="blue">effective</font>; and         •   obtain  <font color="blue">regulatory</font>  approval  from  the  FDA or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We will have to curtail, redirect or eliminate our product <font color="blue">development</font>     programs if we or our <font color="blue">collaborative</font> partners find that:         •  <font color="blue">the AcuForm </font><font color="blue">technology</font> has unintended or undesirable side effects; or         •        products  that appear promising in preclinical or early-stage     <font color="blue">clinical studies</font> do not <font color="blue">demonstrate efficacy</font> in later-stage, larger scale     <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>Even  when  or  if our products obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, successful     <font color="blue">commercialization</font> requires:         •  <font color="blue">market acceptance</font>;         •  cost-<font color="blue">effective</font> commercial scale production; and         •  <font color="blue"><font color="blue">reimbursement</font> under private</font> or <font color="blue"><font color="blue">government</font>al health</font> plans</td>
    </tr>
    <tr>
      <td>Any material delay or failure in the <font color="blue">government</font>al approval process and/or     the <font color="blue">commercialization</font> of our <font color="blue">potential products</font>, particularly Glumetza or     ProQuin XR, would adversely impact our <font color="blue">financial position</font> and liquidity and     would make it <font color="blue">difficult</font> for us to <font color="blue">raise financing on</font> favorable terms, if at     all</td>
    </tr>
    <tr>
      <td>If we do not achieve our projected <font color="blue">development</font> and <font color="blue">commercialization</font> goals     in the timeframes we announce and expect, the <font color="blue">commercialization</font> of our     product <font color="blue">candidates</font> may be delayed and our business will be harmed</td>
    </tr>
    <tr>
      <td>For planning purposes, we estimate the timing of the <font color="blue">accomplishment</font> of     various scientific, clinical, <font color="blue">regulatory</font> and other product <font color="blue">development</font> and     <font color="blue">commercialization</font> goals</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">milestones</font> may</font> include our <font color="blue">expectations</font>     regarding the <font color="blue">commercial launch</font> of our <font color="blue">products by us</font> or our licensees, and     the <font color="blue">commencement</font> or <font color="blue">completion</font> of <font color="blue">scientific studies</font> and <font color="blue">clinical trial</font>s and     the submission of <font color="blue">regulatory</font> filings</td>
    </tr>
    <tr>
      <td>From time to time, we <font color="blue">may publicly</font>     announce  the expected timing of some of these <font color="blue">milestones</font>, such as the     <font color="blue">commercial launch</font> of the 500mg strength of <font color="blue">Glumetza in the United States</font> or     the <font color="blue">commencement</font> of the <font color="blue">Phase III </font><font color="blue">clinical trial</font> of <font color="blue">Gabapentin GR </font>All of     these <font color="blue">milestones</font> are based on a variety of <font color="blue">assumptions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">actual timing</font> of     these <font color="blue">milestones</font> can <font color="blue">vary considerably from</font> our estimates <font color="blue">depending on</font>     <font color="blue">numerous factors</font>, some of which are beyond our control, including:         •  our <font color="blue">available capital resources</font>;         •  the efforts of our <font color="blue">licensees <font color="blue">with respect</font></font> to the <font color="blue">commercialization</font> of our     products;                                           16     ______________________________________________________________________         •       the rate of progress, costs and results of our <font color="blue">clinical trial</font> and     research and <font color="blue">development</font> activities, including the extent of scheduling     <font color="blue">conflicts with participating clinicians</font> and <font color="blue">clinical institutions</font> and our     ability to identify and <font color="blue">enroll patients</font> who meet <font color="blue">clinical trial</font> eligibility     criteria;         •  our receipt of <font color="blue">approvals by</font> the FDA and other <font color="blue">regulatory</font> agencies and the     <font color="blue">timing thereof</font>;         •       other <font color="blue">actions by regulators</font>;         •       our ability to access sufficient, reliable and <font color="blue">affordable supplies</font>     of <font color="blue">components used</font> in the <font color="blue">manufacture</font> of our product <font color="blue">candidates</font>, including     insulin and materials for our GR System; and         •       the costs of ramping up and maintaining <font color="blue">manufacturing</font> <font color="blue">operations</font>, as     <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>If we fail to achieve our announced <font color="blue">milestones</font> in the timeframes we announce     and expect, our business and results of <font color="blue">operations</font> may be harmed and the     price of our <font color="blue">stock may decline</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain or maintain <font color="blue"><font color="blue">regulatory</font> approval</font>, we will be     limited in our ability to <font color="blue">commercialize</font> our products, and our business will     be harmed</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process is expensive and time consuming</td>
    </tr>
    <tr>
      <td>Even after investing     <font color="blue">significant</font> time and expenditures on <font color="blue">clinical trial</font>s, we may not obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Data obtained <font color="blue">from clinical</font>     trials are susceptible to <font color="blue">varying interpretations</font> that could delay, limit or     prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">clinical trial</font> delays would impair     our ability to <font color="blue">commercialize</font> our products and <font color="blue">could allow</font> our <font color="blue">competitors</font> to     <font color="blue">bring products</font> to market before we do</td>
    </tr>
    <tr>
      <td>In addition, changes in <font color="blue">regulatory</font>     policy for <font color="blue">product approval during</font> the period of product <font color="blue">development</font> and     <font color="blue">regulatory</font> agency review of <font color="blue">each submitted new application may</font> cause delays     or <font color="blue">rejections</font></td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font>, this <font color="blue">approval may</font>     <font color="blue">entail limitations on</font> the <font color="blue">indicated uses</font> for which we can market a product</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">with respect</font> to our approved products, once <font color="blue"><font color="blue">regulatory</font> approval</font> is     obtained, a <font color="blue">marketed product</font> and its <font color="blue">manufacture</font>r are subject to continual     review</td>
    </tr>
    <tr>
      <td>The <font color="blue">discovery</font> of <font color="blue">previously unknown problems with</font> a product or     <font color="blue">manufacture</font>r may result in <font color="blue">restrictions on</font> the product, <font color="blue">manufacture</font>r or     <font color="blue">manufacturing</font> facility, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of approved products are also subject to ongoing regulation,     including  compliance  with  FDA  <font color="blue">regulations</font>  governing  current Good     Manufacturing  Practices  (cGMP)</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">manufacturing</font>     <font color="blue">regulations</font> can result in, among other things, warning letters, fines,     <font color="blue">injunctions</font>,  civil penalties, recall or seizure of products, total or     partial  suspension  of production, refusal of the <font color="blue">government</font> to renew     <font color="blue">marketing applications</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">approval process outside</font> the <font color="blue">United States </font>is uncertain and may limit     our ability to develop, <font color="blue">manufacture</font> and sell our <font color="blue">products internationally</font></td>
    </tr>
    <tr>
      <td>To market any of our <font color="blue">products outside</font> of the United States, we and our     <font color="blue">collaborative</font> partners, including Madaus and LG Life Sciences, are subject     to numerous and varying foreign <font color="blue">regulatory</font> <font color="blue">requirements</font>, implemented by     foreign  health <font color="blue">authorities</font>, governing the design and conduct of human     <font color="blue">clinical trial</font>s and <font color="blue">marketing approval</font> for <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>The approval     <font color="blue">procedure varies among countries</font> and can <font color="blue">involve additional testing</font>, and the     time required to obtain <font color="blue">approval may</font> differ from that required to obtain FDA     approval</td>
    </tr>
    <tr>
      <td>The foreign <font color="blue"><font color="blue">regulatory</font> approval</font> process includes all of the risks     <font color="blue">associated with</font> obtaining FDA <font color="blue">approval set forth</font> above, and <font color="blue">approval by</font> the     FDA does not ensure <font color="blue">approval by</font> the health <font color="blue">authorities</font> of any other country,     nor does the <font color="blue">approval by</font> foreign health <font color="blue">authorities</font> ensure <font color="blue">approval by</font> the     FDA         If we or our licensees are unable to obtain acceptable prices or adequate     <font color="blue">reimbursement</font> for our products from third-party payers, we will be unable to     generate <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>In <font color="blue">both domestic</font> and foreign markets, sales of our product <font color="blue">candidates</font> will     depend  in  part  on  the  <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> from     third-party payers such as:         •       <font color="blue">government</font> health administration <font color="blue">authorities</font>;         •       <font color="blue">private health insurers</font>;         •       <font color="blue">health maintenance organizations</font>;         •       pharmacy benefit <font color="blue">management</font> companies; and                                           17     ______________________________________________________________________         •       other healthcare-related organizations</td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> is not available for our products or product <font color="blue">candidates</font>,     demand for these <font color="blue">products may</font> be limited</td>
    </tr>
    <tr>
      <td>Further, any delay in receiving     approval for <font color="blue">reimbursement</font> from third-party payers would have an adverse     effect  on  our  future  revenues</td>
    </tr>
    <tr>
      <td>Third-party payers are <font color="blue">increasingly</font>     <font color="blue">challenging</font>  the  price and cost-<font color="blue">effective</font>ness of <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of     <font color="blue">newly approved healthcare products</font>, including <font color="blue">pharmaceuticals</font></td>
    </tr>
    <tr>
      <td>Our products     may not be considered cost <font color="blue">effective</font>, and adequate third-party <font color="blue">reimbursement</font>     may be unavailable to <font color="blue">enable us</font> to maintain <font color="blue">price levels sufficient</font> to     realize an acceptable return on our <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Federal and state <font color="blue">government</font>s in the <font color="blue">United States </font>and foreign <font color="blue">government</font>s     continue to propose and pass new <font color="blue">legislation</font> designed to contain or reduce     the cost of healthcare</td>
    </tr>
    <tr>
      <td>Existing <font color="blue">regulations</font> affecting pricing may also     change before many of our product <font color="blue">candidates</font> are approved for marketing</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control initiatives could decrease</font> the price that we receive for any     product we may develop</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on third parties</font> who are <font color="blue">single source suppliers</font> to <font color="blue">manufacture</font>     ProQuin  XR, Glumetza and our later stage product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If these     suppliers are unable to <font color="blue">manufacture</font> ProQuin XR, Glumetza or our product     <font color="blue">candidates</font>, our business will be harmed</td>
    </tr>
    <tr>
      <td>We are responsible for <font color="blue">supplying commercial quantities</font> of <font color="blue">ProQuin XR </font>to     Esprit</td>
    </tr>
    <tr>
      <td>For the <font color="blue">manufacture</font>r of <font color="blue">ProQuin XR </font>tablets, we have <font color="blue">entered into</font> an     <font color="blue">agreement with</font> MOVA Pharmaceuticals, as our <font color="blue">sole supplier</font></td>
    </tr>
    <tr>
      <td>Uquifa Mexico,     SA, our supplier of the <font color="blue">active pharmaceutical</font> ingredient to ProQuin XR, is     also a <font color="blue">sole supplier</font> to us</td>
    </tr>
    <tr>
      <td>We obtain the <font color="blue">active pharmaceutical</font> ingredient     to <font color="blue">ProQuin XR </font>on a purchase order <font color="blue">basis only</font></td>
    </tr>
    <tr>
      <td>If we are unable, for whatever     reason, to obtain the <font color="blue">active pharmaceutical</font> ingredient or <font color="blue">ProQuin XR </font>tablets     from our contract <font color="blue">manufacture</font>rs, we may not be able to <font color="blue">manufacture</font> ProQuin     XR in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently negotiating</font> a <font color="blue">supply arrangement with</font> a tablet <font color="blue">manufacture</font>r     for the 500mg strength of Glumetza, and we plan to purchase the active     ingredient for the 500mg Glumetza on a purchase order basis</td>
    </tr>
    <tr>
      <td>If the new     <font color="blue">formulation</font> of 1000mg Glumetza is approved, we <font color="blue">will rely on</font> Biovail as our     <font color="blue">sole supplier</font></td>
    </tr>
    <tr>
      <td>We will be unable to <font color="blue">manufacture</font> Glumetza in a <font color="blue">timely manner</font>     if  we  are  unable  to  obtain  <font color="blue">Glumetza  </font>500mg tablets from contract     <font color="blue">manufacture</font>rs  or  <font color="blue">active pharmaceutical</font> ingredient <font color="blue">from suppliers</font>, or     Glumetza 1000mg tablets from Biovail</td>
    </tr>
    <tr>
      <td>Although we have obtained <font color="blue">clinical batches</font> of <font color="blue">Gabapentin GR </font>from a contract     <font color="blue">manufacture</font>r, we currently have no long-term supply arrangement <font color="blue">with respect</font>     to <font color="blue">Gabapentin GR </font>        If  we choose to acquire new and complementary businesses, products or     <font color="blue">technologies</font> instead of developing <font color="blue">them ourselves</font>, we may be unable to     complete these <font color="blue"><font color="blue">acquisition</font>s</font> or to <font color="blue"><font color="blue">successfully</font> integrate them</font> in a cost     <font color="blue">effective</font> and non-disruptive manner</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to <font color="blue">continually enhance</font> and broaden our     <font color="blue">product offerings</font> in response to changing customer demands, <font color="blue">competitive</font>     pressures and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Accordingly, we may in the <font color="blue">future pursue</font> the     <font color="blue">acquisition</font> of complementary businesses, products or <font color="blue">technologies</font> instead of     developing <font color="blue">them ourselves</font></td>
    </tr>
    <tr>
      <td>We have no current commitments <font color="blue">with respect</font> to     any <font color="blue">acquisition</font> or such <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We do not know if we would be able to     <font color="blue">successfully</font> complete any <font color="blue"><font color="blue">acquisition</font>s</font>, or whether we would be able to     <font color="blue">successfully</font> integrate any acquired business, product or <font color="blue">technology</font> or     retain any <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any business, product or <font color="blue">technology</font> we     acquire could be expensive and time consuming, disrupt our ongoing business     and  distract our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>If we were to be unable to integrate any     acquired businesses, products or <font color="blue">technologies</font> <font color="blue">effective</font>ly, our business     <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">amortization</font> or charges resulting from the     costs of <font color="blue"><font color="blue">acquisition</font>s</font> could harm our operating results</td>
    </tr>
    <tr>
      <td>We have implemented certain anti-takeover provisions</td>
    </tr>
    <tr>
      <td>Certain provisions of our articles of <font color="blue">incorporation</font> and the California     General Corporation Law <font color="blue">could discourage</font> a <font color="blue">third party</font> from acquiring, or     make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire, control of our company     <font color="blue">without approval</font> of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could also</font>     limit the price that <font color="blue">certain investors might</font> be willing to pay in the future     for  shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">provisions allow</font> the board of     <font color="blue">directors</font> to authorize the issuance of <font color="blue">preferred stock with rights</font> superior     to those of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________         We are also subject to the provisions of Section 1203 of the California     General Corporation Law which requires a <font color="blue">fairness opinion</font> to be provided to     our <font color="blue">shareholders</font> in <font color="blue">connection with</font> their <font color="blue">consideration</font> of any proposed     “interested party” reorganization transaction</td>
    </tr>
    <tr>
      <td>We have adopted a <font color="blue">shareholder rights</font> plan, <font color="blue">commonly known as</font> a “poison     pill”</td>
    </tr>
    <tr>
      <td>The provisions described above, our <font color="blue">poison pill</font> and provisions of the     <font color="blue">California General Corporation Law </font>may discourage, delay or prevent a third     <font color="blue">party from</font> acquiring us</td>
    </tr>
    <tr>
      <td><font color="blue">Increased  </font>costs  associated  <font color="blue">with <font color="blue">corporate governance</font> compliance may</font>     <font color="blue">significant</font>ly impact our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>,     <font color="blue">public <font color="blue">disclosure</font></font> and <font color="blue">compliance practices</font>, including the Sarbanes-Oxley Act     of 2002, new SEC <font color="blue">regulations</font> and <font color="blue">Nasdaq National Market </font>rules, are creating     <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font> in understanding and <font color="blue">complying with</font>     these laws, <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>As a result of this <font color="blue">uncertainty</font> and     other factors, devoting the <font color="blue">necessary</font> resources to <font color="blue">comply with</font> evolving     <font color="blue">corporate governance</font> and <font color="blue">public <font color="blue">disclosure</font></font> standards has resulted in and may     in the future result in <font color="blue">increased general</font> and <font color="blue"><font color="blue">administrative</font> expenses</font> and a     diversion of <font color="blue">management</font> time and attention to <font color="blue">compliance activities</font></td>
    </tr>
    <tr>
      <td>We also     expect these <font color="blue">development</font>s to increase our <font color="blue">legal compliance</font> and financial     reporting costs</td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">development</font>s may make it more <font color="blue">difficult</font>     and  more  expensive  for  us to obtain director and <font color="blue">officer liability</font>     insurance,  and we may be required to <font color="blue">accept reduced coverage</font> or incur     <font color="blue">substantially higher costs</font> to obtain coverage</td>
    </tr>
    <tr>
      <td>Moreover, we may not be able     to <font color="blue">comply with</font> these new rules and <font color="blue">regulations</font> on a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">development</font>s could make it more <font color="blue">difficult</font> for us to attract and retain     qualified  members  of  our board of <font color="blue">directors</font>, or <font color="blue">qualified executive</font>     officers</td>
    </tr>
    <tr>
      <td>We are <font color="blue">presently evaluating</font> and monitoring <font color="blue">regulatory</font> <font color="blue">development</font>s     and cannot estimate the timing or magnitude of <font color="blue">additional costs</font> we may incur     as a result</td>
    </tr>
    <tr>
      <td>To the extent these costs are <font color="blue">significant</font>, our general and     <font color="blue"><font color="blue">administrative</font> expenses</font> are likely to increase</td>
    </tr>
    <tr>
      <td>If we are unable to satisfy <font color="blue">regulatory</font> <font color="blue">requirements</font> relating to internal     controls, our <font color="blue">stock price could suffer</font></td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 requires companies to do a     <font color="blue">comprehensive</font> <font color="blue">evaluation</font> of their internal control over financial reporting</td>
    </tr>
    <tr>
      <td>At  the  end of each fiscal year, we must perform an <font color="blue">evaluation</font> of our     internal control over financial reporting, include in our annual report the     results of the <font color="blue">evaluation</font>, and have our <font color="blue">external auditors publicly attest</font> to     such <font color="blue">evaluation</font></td>
    </tr>
    <tr>
      <td>If we fail to complete future <font color="blue">evaluation</font>s on time, or if     our <font color="blue">external auditors cannot attest</font> to our future <font color="blue">evaluation</font>s, we could fail     to meet our <font color="blue">regulatory</font> reporting <font color="blue">requirements</font> and be subject to <font color="blue">regulatory</font>     scrutiny and a loss of <font color="blue">public confidence</font> in our internal controls, which     could have an adverse effect on our stock price</td>
    </tr>
    <tr>
      <td>Business <font color="blue"><font color="blue">interruption</font>s could limit</font> our ability to operate our business</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font> are vulnerable to damage or <font color="blue"><font color="blue">interruption</font> from computer</font>     viruses,  human error, natural disasters, telecommunications failures,     <font color="blue">intentional</font>  acts  of vandalism and similar events</td>
    </tr>
    <tr>
      <td>In particular, our     <font color="blue">corporate headquarters</font> are located in the <font color="blue">San Francisco Bay </font>area, which has     a history of <font color="blue">seismic activity</font></td>
    </tr>
    <tr>
      <td>We have not established a formal disaster     recovery plan, and our back-up <font color="blue">operations</font> and our business <font color="blue">interruption</font>     <font color="blue">insurance may</font> not be adequate to <font color="blue">compensate us</font> for losses that occur</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font> business <font color="blue">interruption</font> could result in losses or <font color="blue">damages incurred</font>     by us and require us to cease or curtail our <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>